Fulminant Giant Cell Myocarditis following Heterologous Vaccination of ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19

Fulminant Giant Cell Myocarditis following Heterologous Vaccination of ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19

A 48-year-old female patient underwent a heart transplantation for acute fulminant myocarditis, following heterologous vaccination with the ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19. She had no history of severe acute respiratory syndrome coronavirus-2 infection. She did not exhibit clinical sign...

Full description

Bibliographic Details
Main Authors: Dong-Hoon Kang, Joo-Young Na, Jun-Ho Yang, Seong-Ho Moon, Sung-Hwan Kim, Jae-Jun Jung, Ho-Jeong Cha, Jong-Hwa Ahn, Yong-Whi Park, Sang-Yeong Cho, Ho-Kyung Yu, Soo-Hee Lee, Mi-Yeong Park, Jong-Woo Kim, Joung-Hun Byun
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Medicina
Subjects:
COVID-19
vaccination
giant cell myocarditis
Online Access:https://www.mdpi.com/1648-9144/58/3/449

Internet

https://www.mdpi.com/1648-9144/58/3/449

Similar Items